跳至主要内容
临床试验/NL-OMON24360
NL-OMON24360招募中不适用

Cohort study for the treatment of unruptured intracranial aneurysms with flow diverters

Radboudumc0 个研究点目标入组 83 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
Radboudumc
入组人数
83

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Suitability for FD treatment or alternative treatment will be identified according to the following inclusion criteria:
  • - unruptured intracranial aneurysm of internal carotid artery;
  • - unfavourable dome neck configuration (=2), or neck =4 mm, or maximum aneurysm diameter =10 mm; or tandem aneurysms with any configuration; multisegmental disease;
  • - =18 years;
  • - modified Rankin Scale (mRS) =2;
  • - patients willing to provide written informed consent and comply with follow up requirements.
  • Patients eligible for FD but treated otherwise in the Radboudumc and patients eligible for this study and treated with FD in other centres should also be included in the study. A registry will be kept of patients treated with FD who did not meet the inclusion criteria for this study.

排除标准

  • - intracranial hemorrhage within 30 days;
  • - presence of untreated ruptured intracranial aneurysm;
  • - =1 intracranial aneurysm except the target one which requires treatment within 12 months;
  • - contra-indication for dual antiplatelet therapy;
  • - known allergy or inadequate response to aspirin, heparin, clopidogrel, ticagrelor or prasugrel, other anti-platelet or P2Y12 agents or to general anesthesia (platelet reactivity will be assessed prior to the inclusion in patients who require anti-platelet or P2Y12 agents following the treatment);
  • - bifurcation aneurysm (e.g. pcom aneurysm with fetal or intermediate configuration where pcom cannot be occluded);
  • - immunosuppressive disease;
  • - active infectious disease (e.g. endocarditis, meningitis);
  • - platelet count < 100 x 103 cells/mm3 or known platelet dysfunction at time of enrollment;
  • - female of child-bearing potential who are unable to take adequate contraceptive precautions, are known to be pregnant, or are currently breastfeeding an infant;
  • - intracranial aneurysm correlating to arteriovenous malformation, dissecting aneurysms;
  • - patient with another unrelated intracranial disease and patients with any type of malignancy;
  • - major surgery within previous 30 days or planned in the next 120 days after enrolment;
  • - patient with a periprocedural International Normalized Ratio (INR)= 1.5;
  • - patient with any condition that, in the opinion of the treating physician, would place the participant at a high risk of embolic stroke or with any medical co-morbidity likely to affect the outcome (e.g. pulmonary disease, uncontrolled diabetes, protrombotic conditions, e.g. factor 5 Leiden);
  • - patient with a life threatening allergy to iodinated contrast media (patients with itching or rash as a reaction to contrast can be included if properly prophylactically treated);
  • - patient who is currently participating in another clinical research study involving an investigational product;
  • - stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to the treatment date;
  • - unstable neurological deficit (i.e. worsening or improvement of clinical condition in the last 30 days unrelated to the aneurysm);
  • - patient who has participated in a drug study within the last 30 days;
  • - inability to understand the study or history of non-compliance with medical advice;
  • - patient who has had a previous intracranial procedure associated with the target aneurysm such that access and placement of an investigational device would be compromised.

研究者

发起方
Radboudumc

相似试验